Pfizer has Announced a Promising Treatment with Pills against COVID-19

Tests of experimental antiviral treatment against COVID-19 by the American company "Pfizer" (Pfizer) in the form of a pill have proved so promising that they have been shortened. The reason is that it reduced by 89% the risk of hospitalization or death in adults at risk of developing a severe form of the disease.

The news was announced by the company itself, referring to data from the second of three phases of testing. Detailed information has not been disseminated. There are no details about treatment side effects, and the report said that some "side effects" were reported in about 20% of those treated with the experimental therapy and the placebo group. A familiar approach has been used, in which cases such as nausea and vomiting have been reported in other cases by other companies.

If the report is confirmed by independent evaluators, the result will be more effective than that of the pill of the American "Merck" (Merck & Co Inc.), which was approved for use yesterday - albeit very limited - in the UK. Merck is about people with at least one concomitant condition such as diabetes or cardiovascular disease.

Reuters explains that, according to infectious disease experts, preventing COVID-19 through mass vaccination remains the best way to control the pandemic.

Pfizer said it plans to present the interim results for the FDA regulator's pill as part of an emergency approval application that began in October (a regime that does not recognize the product for normal use but is considered to be in critical situation, its benefits outweigh the potential risks).

It is a combination treatment under the brand name "Paxlovid" (Paxlovid), which includes ritonavir (ritonavir) - another antiviral drug. The dosage is 3 pills 2 times a day.

...